Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 18/20 | 0.52 |
| ▸ | MAP2K2 | P36507 | 12/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.41 |
| ▸ | BRAF | P15056 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL392113 | 0.87 | MAP2K1 (0.56) | MAP2K1MAP2K2CA2IDO1PIM1 | |
| SCHEMBL935637 | 0.83 | MAP2K1 (0.50) | MAP2K1MAP2K2CA2PIM1CAMK2B | |
| SCHEMBL391034 | 0.80 | MAP2K1 (0.52) | MAP2K1MAP2K2PIM1CAMK2BBRAF | |
| SCHEMBL16322268 | 0.80 | MAP2K1 (0.55) | MAP2K1MAP2K2PIM1CAMK2BBRAF | |
| SCHEMBL13672936 | 0.79 | MAP2K1 (0.52) | MAP2K1MAP2K2IDO1PIM1CAMK2B | |
| SCHEMBL390960 | 0.77 | MAP2K1 (0.63) | MAP2K1MAP2K2PIM1CAMK2BBRAF | |
| SCHEMBL15061750 | 0.77 | MAP2K1 (0.54) | MAP2K1MAP2K2IDO1PIM1CAMK2B | |
| SCHEMBL11929738 | 0.77 | MAP2K1 (0.49) | MAP2K1MAP2K2IDO1PIM1CAMK2B | |
| SCHEMBL345623 | 0.77 | MAP2K1 (0.52) | MAP2K1MAP2K2CA2PIM1CAMK2B | |
| SCHEMBL392144 | 0.77 | MAP2K1 (0.52) | MAP2K1MAP2K2PIM1CAMK2BBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2854779-A1 | BIOMARKERS FOR DETERMINING EFFECTIVE RESPONSE OF TREATMENTS OF HEPATOCELLULAR CARCINOMA (HCC) PATIENTS | Bayer Pharma Aktiengesellschaft (DE) | 2015-04-08 | — | — | EP | disclosed |
| WO-2013178581-A1 | BIOMARKERS FOR DETERMINING EFFECTIVE RESPONSE OF TREATMENTS OF HEPATOCELLULAR CARCINOMA (HCC) PATIENTS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2013-12-05 | — | — | WO | disclosed |
| US-8101799-B2 | Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK | ARDEA BIOSCIENCES (US) | 2012-01-24 | — | — | US | disclosed |
| US-7759518-B2 | (S)-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide; MEK kinase (mitogen-activated ERK-activating kinases, MAP kinase kinase); cancer, tumors, autoimmune disorders, ischemia, rheumatoid arthritis, multiple sclerosis, psoriasis, restenosis | ARDEA BIOSCIENCES (US) | 2010-07-20 | — | — | US | disclosed |
| US-20090082457-A1 | (S)-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide; MEK kinase (mitogen-activated ERK-activating kinases, MAP kinase kinase); cancer, tumors, autoimmune disorders, ischemia, rheumatoid arthritis, multiple sclerosis, psoriasis, restenosis | ANDREA BIOSCIENCES, INC. (US) | 2009-03-26 | — | — | US | disclosed |
| US-20080058340-A1 | MEK kinase (mitogen-activated ERK-activating kinases or MAP kinase kinase); cancer, tumors, infections, autoimmune disorders, stroke, ischemia, rheumatoid arthritis, multiple sclerosis, psoriasis, restenosis; 1-sulfonamido-2-(phenylamino)-4-fluorobenzene compounds | ARDEA BIOSCIENCES, INC. (US) | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058340-A1 | MEK kinase (mitogen-activated ERK-activating kinases or MAP kinase kinase); cancer, tumors, infections, autoimmune disorders, stroke, ischemia, rheumatoid arthritis, multiple sclerosis, psoriasis, restenosis; 1-sulfonamido-2-(phenylamino)-4-fluorobenzene compounds | BRAF, MAPK1, MAPK12 | MAP2K1 32/4885MAP2K2 23/4885CA2 4731/4885 |
| US-20090082457-A1 | (S)-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide; MEK kinase (mitogen-activated ERK-activating kinases, MAP kinase kinase); cancer, tumors, autoimmune disorders, ischemia, rheumatoid arthritis, multiple sclerosis, psoriasis, restenosis | BRAF, MAPK1, MAP2K2 | MAP2K1 7/4885MAP2K2 3/4885CA2 4058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.